UNBX — Unity Biotechnology Share News
0.000.00%
Last trade - 00:00Unity Biotechnology Inc Expected To Post A Loss Of 72 Cents A Share: Earnings Preview
Brief: Unity Biotechnology Doses First Patients In Phase 2 ASPIRE Study of UBX1325 in DME
Brief: Unity Biotechnology Files For Secondary Offering Of Up To $2.3 mln Shares Of Common Stock
Brief: Unity Biotechnology Q3 Operating Income USD -14.931 Million
Brief: UNITY Biotechnology Announces Exercise of Warrants for $4.38 Mln in Gross Proceeds
Unity Biotechnology Inc Expected To Post A Loss Of 96 Cents A Share: Earnings Preview
U.S. STOCKS ON THE MOVE-Nucor, Liberty Energy, Micron Technology
U.S. STOCKS ON THE MOVE-SoundHound, Tesla, Energy firms
Unity Biotechnology rises on eye disorder drug trial data
Brief: Unity Biotechnology Announces 48-Week Results From Phase 2 Envision Study Of Ubx1325 In Patients With Wet Age-Related Macular Degeneration
Unity Biotechnology Inc Reports Results For The Quarter Ended In June: Earnings Summary
Unity Biotechnology Inc Expected To Post A Loss Of 86 Cents A Share: Earnings Preview
Brief: UNITY Biotechnoogy Announces Design Of Phase 2B ASPIRE Study Evaluating UBX1325 In Diabetic Macular Edema
Unity Biotechnology Inc Reports Results For The Quarter Ended In March: Earnings Summary
Unity Biotechnology Inc Expected To Post A Loss Of $1.08 A Share: Earnings Preview
U.S. STOCKS ON THE MOVE-Bed Bath & Beyond, Foghorn Therapeutics, Bluebird Bio
Unity Biotechnology up on positive results from follow-up drug trial
Brief: UNITY Biotechnology Gives Positive 48-Week Results From Phase 2 BEHOLD Study Of UBX1325
Wedbush slashes Unity Biotech's PT after eye drug failed mid-stage study